Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas E Johnson

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Muscle & Nerve|June 6, 2015
Myotonic dystrophy health index: Correlations with clinical tests and patient functionChad Heatwole, Rita Bode, Nicholas E Johnson, et al.
Nature Genetics|July 16, 2021
p53 convergently activates Dux/DUX4 in embryonic stem cells and in facioscapulohumeral muscular dystrophy cell modelsEdward J Grow, Bradley D Weaver, Christina M Smith, et al.
BMC Neurology|September 12, 2019
Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective studySamantha LoRusso, Nicholas E Johnson, Michael P McDermott, et al.
NAR Molecular Medicine|February 19, 2026
Identification of enzymatically modified isoquercitrin as a therapeutic lead for myotonic dystrophy type 1Subodh K Mishra, Sawyer M Hicks, Jesus A Frias, et al.
Neurology|October 28, 2025
Expert Consensus on Genetic Diagnostic Approaches for Patients With Limb-Girdle Muscular DystrophyVolker Straub, Amanda R Clause, Sandra Donkervoort, et al.
Neurology. Genetics|October 27, 2022
Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices: The IPaNeMA StudyMarie Wencel, Aziz Shaibani, Namita A Goyal, et al.
Neuromuscular Disorders : NMD|February 20, 2025
Strength and functional correlates of reachable workspace in facioscapulohumeral muscular dystrophyLeo H Wang, Maya N Hatch, Michael P McDermott, et al.
The New England Journal of Medicine|February 18, 2026
An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1Nicholas E Johnson, Li-Jung Tai, Johanna I Hamel, et al.
Neuromuscular Disorders : NMD|March 20, 2026
Late-onset facioscapulohumeral muscular dystrophy defines a distinct clinical subgroupGiulia Tammam, Sandra Dhifallah, Hongmei Yang, et al.
ACS Chemical Biology|February 20, 2026
Modified Polycyclic Compounds Rescue Mis-splicing in Myotonic Dystrophy Type 1 Disease ModelsJesus A Frias, Sawyer M Hicks, Hormoz Mazdiyasni, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Muscle & Nerve|June 6, 2015
Myotonic dystrophy health index: Correlations with clinical tests and patient functionChad Heatwole, Rita Bode, Nicholas E Johnson, et al.
Nature Genetics|July 16, 2021
p53 convergently activates Dux/DUX4 in embryonic stem cells and in facioscapulohumeral muscular dystrophy cell modelsEdward J Grow, Bradley D Weaver, Christina M Smith, et al.
BMC Neurology|September 12, 2019
Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective studySamantha LoRusso, Nicholas E Johnson, Michael P McDermott, et al.
NAR Molecular Medicine|February 19, 2026
Identification of enzymatically modified isoquercitrin as a therapeutic lead for myotonic dystrophy type 1Subodh K Mishra, Sawyer M Hicks, Jesus A Frias, et al.
Neurology|October 28, 2025
Expert Consensus on Genetic Diagnostic Approaches for Patients With Limb-Girdle Muscular DystrophyVolker Straub, Amanda R Clause, Sandra Donkervoort, et al.
Neurology. Genetics|October 27, 2022
Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices: The IPaNeMA StudyMarie Wencel, Aziz Shaibani, Namita A Goyal, et al.
Neuromuscular Disorders : NMD|February 20, 2025
Strength and functional correlates of reachable workspace in facioscapulohumeral muscular dystrophyLeo H Wang, Maya N Hatch, Michael P McDermott, et al.
The New England Journal of Medicine|February 18, 2026
An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1Nicholas E Johnson, Li-Jung Tai, Johanna I Hamel, et al.
Neuromuscular Disorders : NMD|March 20, 2026
Late-onset facioscapulohumeral muscular dystrophy defines a distinct clinical subgroupGiulia Tammam, Sandra Dhifallah, Hongmei Yang, et al.
ACS Chemical Biology|February 20, 2026
Modified Polycyclic Compounds Rescue Mis-splicing in Myotonic Dystrophy Type 1 Disease ModelsJesus A Frias, Sawyer M Hicks, Hormoz Mazdiyasni, et al.
Pageof 10